Horizon Therapeutics Public Limited Company
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Horizon Therapeutics Public Limited Company generated cash of $1,257,842,000, which is more than the previous year. Cash used in financing activities reached the amount of -$347,958,000 last year. Net change in cash is therefore $773,432,000.
Cash Flow
| 2013 | -54.28M | -36.13M | 66.71M |
|---|---|---|---|
| 2014 | 27.54M | -227.72M | 338.28M |
| 2015 | 194.16M | -995.04M | 1.44B |
| 2016 | 369.45M | -1.37B | 657.07M |
| 2017 | 280.20M | -101.61M | 58.40M |
| 2018 | 194.54M | 27.65M | -16.59M |
| 2019 | 426.33M | -17.85M | -290.44M |
| 2020 | 555.68M | -464.07M | 904.57M |
| 2021 | 1.03B | -2.99B | 1.47B |
| 2022 | 1.25B | -134.00M | -347.95M |
HZNP Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.58B | 2.08B | 1.08B | 962.11M | 757.89M | 509.05M | 859.61M | 218.80M | 80.48M | 104.08M |
Operating activities | ||||||||||
Net income | 521.48M | 534.49M | 389.79M | 573.02M | -74.18M | -410.52M | -166.83M | 39.53M | -263.60M | -149.00M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 390.39M | 353.75M | 279.45M | 237.15M | 275.72M | 283.41M | 221.83M | 138.34M | 34.00M | 9.31M |
Stock-based compensation expense | 182.1M | 219.08M | 146.62M | 91.21M | 114.86M | 125.01M | 113.01M | 83.55M | 13.19M | 5.01M |
| Deferred income tax benefit | 182.1M | 219.08M | 146.62M | 91.21M | 114.86M | 125.01M | 113.01M | 83.55M | 13.19M | 5.01M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -43.45M | 34.79M | -251.17M | 56.16M | -59.69M | -61.82M | -67.49M | -124.76M | -46.18M | -12.49M |
Inventories | 56.12M | 1.26M | -21.45M | -3.26M | 10.28M | 108.37M | 67.63M | 12.21M | 7.17M | -3.42M |
Accounts payable | 122.23M | -12.19M | 16.01M | -8.72M | -4.59M | -16.52M | 32.06M | -8.36M | 9.38M | 3.90M |
Cash generated by operating activities | 1.25B | 1.03B | 555.68M | 426.33M | 194.54M | 280.20M | 369.45M | 194.16M | 27.54M | -54.28M |
Investing activities | ||||||||||
Purchases Of Investments | -9.23M | -24.66M | -13.31M | 0 | 0 | 0 | 0 | -71.81M | 0 | 0 |
Investments In Property Plant And Equipment | -126.27M | -126.16M | -199.85M | -17.85M | -16.77M | -4.33M | -15.73M | -7.15M | -3.5M | -1.19M |
Acquisitions Net | -3.12M | -2.84B | -262.30M | 0 | 0 | -97.84M | -1.35B | -1.02B | -224.22M | -35M |
Cash generated by investing activities | -134.00M | -2.99B | -464.07M | -17.85M | 27.65M | -101.61M | -1.37B | -995.04M | -227.72M | -36.13M |
Financing activities | ||||||||||
Common Stock Issued | 30.31M | 0 | 919.78M | 326.79M | 8.61M | 0 | 0 | 475.68M | 0 | 6.63M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -250.07M | 0 | 0 | 0 | 0 | -992K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -12M | -1.73M | 0 | -845.74M | 0 | -4M | 0 | 0 | -64.84M |
Cash used in financing activities | -347.95M | 1.47B | 904.57M | -290.44M | -16.59M | 58.40M | 657.07M | 1.44B | 338.28M | 66.71M |
Net Change In Cash | 773.43M | -499.32M | 1.00B | 117.92M | 204.22M | 242.31M | -350.56M | 640.80M | 138.32M | -23.60M |
Cash at end of period | 2.35B | 1.58B | 2.08B | 1.08B | 962.11M | 751.36M | 509.05M | 859.61M | 218.80M | 80.48M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |